Rebif and Erbitux prop Merck KGaA's Q3 sales

Merck KGaA reported a 3% increase in group revenues in the third quarter, to €1.94 billion, with strong growth in sales of the multiple sclerosis drug Rebif (interferon beta-1a) and the anticancer Erbitux (cetuximab) bolstering the figure.

Merck KGaA reported a 3% increase in group revenues in the third quarter, to €1.94 billion, with strong growth in sales of the multiple sclerosis drug Rebif (interferon beta-1a) and the anticancer Erbitux (cetuximab) bolstering the figure.

Sales in the company's pharma business, Merck Serono, rose by 6% to €1.31 billion. However, high costs for late-stage clinical...

Welcome to Scrip

Create an account to read this article

More from Anticancer

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Therapeutic Category

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.